Royce & Associates’s Avanos Medical AVNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-60,703
Closed -$1.51M – 787
2026
Q2
$1.51M Sell
60,703
-453,000
-88% -$10.6M 0.01% 646
2026
Q1
$7.2M Buy
513,703
+453,000
+746% +$6.1M 0.07% 406
2025
Q4
$682K Buy
60,703
+28,482
+88% +$326K 0.01% 685
2025
Q3
$372K Buy
+32,221
New +$377K ﹤0.01% 723
2015
Q4
– Sell
-84,500
Closed -$2.4M – 1122
2015
Q3
$2.4M Buy
+84,500
New +$2.95M 0.01% 828

Other funds holding AVNS

Royce & Associates's AVNS Position: Q3 2026 in Review

Royce & Associates sold out of Avanos Medical (AVNS) in Q3 2026, closing a stake of 60,703 shares — an estimated $1.51M sold.

Royce & Associates first reported a position in AVNS in Q3 2015 and held it in 5 quarters. The position peaked at $7.2M in Q1 2026. 3 funds tracked by Wall St. Rank hold AVNS as of Q3 2026.

  • Royce & Associates reported no remaining Avanos Medical position as of Q3 2026 after selling out during the quarter.
  • Royce & Associates sold 60,703 Avanos Medical shares in Q3 2026, an estimated $1.51M.
  • Royce & Associates first reported a position in Avanos Medical in Q3 2015 and held it in 5 quarters.
  • Royce & Associates's Avanos Medical position peaked at $7.2M in Q1 2026.
  • 3 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2026.

Based on Royce & Associates's 13F filing for Q3 2026, filed 9 Nov 2026.